Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OS Therapies Incorporated ( (OSTX) ) has shared an update.
On June 23, 2025, OS Therapies announced a warrant exercise inducement and exchange offer for holders of its five-year warrants initially issued in December 2024. The offer allows holders to exercise their old warrants for new ones at a higher exercise price, potentially generating up to $8 million in gross proceeds. The funds will support regulatory and pre-commercial efforts for OST-HER2, aimed at preventing recurrent lung metastatic osteosarcoma. The company has already received $1.76 million from this initiative, extending its cash runway into the second half of 2026. The new warrants include a forced exercise provision and are part of OS Therapies’ strategy to secure marketing authorization for OST-HER2, which has received a Rare Pediatric Disease Designation from the US FDA.
The most recent analyst rating on (OSTX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on OS Therapies Incorporated stock, see the OSTX Stock Forecast page.
Spark’s Take on OSTX Stock
According to Spark, TipRanks’ AI Analyst, OSTX is a Underperform.
OS Therapies Incorporated faces significant financial difficulties, marked by increasing net losses, negative cash flows, and reliance on external financing. The technical analysis indicates bearish momentum with the stock trading below its moving averages. Valuation is challenging with no earnings to support a P/E ratio or dividend yield. These factors contribute to a low overall stock score, reflecting the company’s financial instability and negative market sentiment.
To see Spark’s full report on OSTX stock, click here.
More about OS Therapies Incorporated
OS Therapies is a clinical-stage oncology company focused on developing treatments for osteosarcoma and other solid tumors. Their lead asset, OST-HER2, is an immunotherapy designed to target the HER2 protein and has received various designations from the US FDA and European Medicines Agency. The company is also advancing its Antibody Drug Conjugate (ADC) platform.
Average Trading Volume: 279,643
Technical Sentiment Signal: Strong Sell
For an in-depth examination of OSTX stock, go to TipRanks’ Overview page.